$NBRV @Zaneyone this from last 10-a page 29 if you want to read it yourself WE EXPECT TO CONTINUE TO INCUR SIGNIFICANT EXPENSES AND HAVE NEGATIVE CASH FLOWS FOR AT LEAST THE NEXT SEVERAL YEARS. Our expenses will increase if we suffer any regulatory delays or are required to conduct additional clinical trials to satisfy regulatory requirements. If we obtain marketing approval for CONTEPO or any other product candidate that we develop, in-license or acquire, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing zane shame on you